Mebutamate

Mebutamate

Mebutamate is a carbamate derivative used as an anxiolytic drug. It is similar in structure and function to barbiturates and is generally considered part of the group of sedative-hypnotic drugs. Mebutamate is primarily used to treat short-term anxiety and tension, and it is marketed under the brand names Equanil and Miltown.

History

Mebutamate was first synthesized in the 1950s and quickly gained popularity as a treatment for anxiety and tension. It was one of the first drugs of its kind, predating the development of benzodiazepines, which are now more commonly used for these purposes.

Pharmacology

Mebutamate acts on the GABA receptor, enhancing the effect of the neurotransmitter GABA in the brain. This results in a calming effect, reducing feelings of anxiety and tension. The drug is rapidly absorbed in the gastrointestinal tract and is metabolized in the liver.

Side Effects

Common side effects of mebutamate include drowsiness, dizziness, and weakness. More serious side effects can include confusion, slow heart rate, and difficulty breathing. Long-term use of mebutamate can lead to physical dependence and withdrawal symptoms if the drug is abruptly discontinued.

Legal Status

In the United States, mebutamate is classified as a Schedule IV controlled substance under the Controlled Substances Act. This means it has a low potential for abuse and low risk of dependence.

See Also

• Carbamates
• Anxiolytic
• GABA receptor
• Controlled Substances Act

‎